News

Pfizer has signed a strategic partnership with the Shanghai Institutes for Biological Sciences (SIBS), to support fundamental research in China. The company said that the research projects will

Bayer Group has reported a decrease in sales by 5.9% to E8 billion for the second quarter of 2009, as compared to E8.51 billion in the second quarter

FDA has approved Roxane’s Abbreviated New Drug Application (ANDA) for its Risperidone Oral Solution, 1mg/mL. Risperidone 1 mg/ml oral solution is indicated for the treatment of schizophrenia. Risperidone

Neurocrine has reported six month safety and efficacy results from its fourth phase II clinical trial – orally-active, non-peptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix – in patients

GlaxoSmithKline (GSK) and Genmab have announced preliminary top-line results from a phase III study of ofatumumab, administered intravenously. The drug is for the treatment of rheumatoid arthritis (RA)

Sciele Pharma and Plethora Solutions have reported results for the second and final phase III double-blind, placebo-controlled study of PSD502, for the treatment of premature ejaculation. PSD502 has

AkzoNobel, a paints, coatings and specialty chemicals company, has posted a decline of 10% in the revenues to E3.66 billion, as compared to previous years E4.08 billion. The

FORMA has entered into a collaboration agreement with Novartis. Under the terms of the agreement, FORMA will utilize its cell-based screening platform to discover inhibitors for undisclosed protein-protein

The European commission has approved broader label for Roche’s Avastin allowing combination with docetaxel for the first-line treatment of advanced (metastatic) breast cancer. Avastin is an antibody that